Home/Filings/4/0001005201-19-000019
4//SEC Filing

Bukofzer Stan 4

Accession 0001005201-19-000019

CIK 0001005201other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 4:19 PM ET

Size

11.6 KB

Accession

0001005201-19-000019

Insider Transaction Report

Form 4
Period: 2019-02-12
Bukofzer Stan
Chief Medical Officer & SVP***
Transactions
  • Award

    Restricted Stock Units

    2019-02-12+82,76382,763 total
    Exp: 2022-02-12Common Stock (82,763 underlying)
  • Award

    Performance Shares

    2019-02-12+18,57018,570 total
    Common Stock (18,570 underlying)
Footnotes (5)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
  • [F2]One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022, assuming continued employment through the applicable vesting date.
  • [F3]The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
  • [F4]Represents the current tranche of performance shares earned under the 2018 performance share award as of February 12, 2019, at which date the Compensation Committee certified the extent to which the current tranche performance criteria were achieved. Each earned performance share represents the contingent right to receive one share of common stock.
  • [F5]Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021.

Issuer

Assertio Therapeutics, Inc

CIK 0001005201

Entity typeother

Related Parties

1
  • filerCIK 0001663041

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:19 PM ET
Size
11.6 KB